NCT00636909View on ClinicalTrials.gov

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 1999

Primary Completion Date

March 31, 2006

Conditions
AMLALLCML Chronic Phase, Accelerated Phase, or Blast CrisisCLLMDSRELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMAAPLASTIC ANEMIAMULTIPLE MYELOMAMYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Interventions
DRUG

Cyclophosphamide

preparative cytoreduction

DRUG

fludarabine

preparative cytoreduction

DRUG

cyclosporine

immunosuppressive therapy

DRUG

methotrexate

immunosuppressive therapy

BIOLOGICAL

G-CSF

foster engraftment

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00636909 - Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | Biotech Hunter | Biotech Hunter